Results 131 to 140 of about 16,960 (244)

Which drugs should post-MI patients routinely receive? [PDF]

, 2010
patients should be placed on the following medications: antiplatelet agents (strength of recommendation [SOR]: A, meta-analysis for aspirin; A, multiple randomized controlled trials [RCTs] for aspirin plus clopidogrel) a statin; atorvastatin has the best
Holman, John R., Jamieson, Barbara, Lin, Victor   +2 more
core  

Analysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: a preliminary report [PDF]

, 2016
[Abstract] Background: Ivabradine, a selective bradycardic drug, inhibits the If. In patients with heart failure (HF), ivabradine reduces the risk of rehospitalization and mortality.
Barge-Caballero, Eduardo, Crespo-Leiro, María Generosa, Grille Cancela, Zulaika, Hermida-Prieto, Manuel, Marrón Liñares, Grecia Manuela, Marzoa Rivas, Raquel, Muñiz, Javier, Núñez, Lucía, Paniagua-Martín, María J., Suárez-Fuentetaja, Natalia, Vázquez-Rodríguez, José Manuel   +10 more
core   +2 more sources

Combination of ADAM17 knockdown with eplerenone is more effective than single therapy in ameliorating diabetic cardiomyopathy

Frontiers in Pharmacology
BackgroundThe renin-angiotensin-aldosterone system (RAAS) members, especially Ang II and aldosterone, play key roles in the pathogenesis of diabetic cardiomyopathy (DCM).
Lin Xie, Dejin Zang, Jianmin Yang, Fei Xue, Wenhai Sui, Yun Zhang, Yun Zhang   +6 more
doaj   +1 more source

Prevention of lipopolysaccharide-induced peritoneal damage by eplerenone in rats undergoing peritoneal dialysis [PDF]

, 2016
埼玉医科大学平成25年
田山 陽資
core  

Hypokalemic rhabdomyolysis: a rare manifestation of primary aldosteronism [PDF]

, 2015
Rhabdomyolysis is a rare presentation of hypokalemia, although muscle weakness is a well-known manifestation of hypokalemia. Primary aldosteronism is characterized by hypertension, suppressed plasma renin activity, increased aldosterone excretion and ...
CONCISTRE, ANTONIO, FIACCO, FEDERICA, LETIZIA, Claudio, MARINELLI, CRISTIANO, MITTERHOFER, Anna Paola, PETRAMALA, LUIGI, TINTI, FRANCESCA, UMBRO, ILARIA, ZAVATTO, ASSUNTA, ZINGARETTI, VIVIANA   +9 more
core  

Eplerenone in patients with systolic heart failure and mild symptoms.

New England Journal of Medicine, 2011
F. Zannad, J. McMurray, H. Krum, D. V. van Veldhuisen, K. Swedberg, Harry Shi, J. Vincent, S. Pocock, B. Pitt   +8 more
semanticscholar   +1 more source

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

New England Journal of Medicine, 2003
B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, Steve Hurley, J. Kleiman, M. Gatlin   +9 more
semanticscholar   +1 more source

Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece

ClinicoEconomics and Outcomes Research, 2016
Kostas Athanasakis,1 Aikaterini Bilitou,2 Dawn Lee,3 Eleftheria Karampli,1 Apostolos Karavidas,4 John Parissis,5 Georgia Sykara,2 John Kyriopoulos1 1Department of Health Economics, National School of Public Health, Athens, Greece; 2Pfizer Hellas, Athens,
Athanasakis K, Bilitou A, Lee D, Karampli E, Karavidas A, Parissis J, Sykara G, Kyriopoulos J   +7 more
doaj  

Тривале спостереження за хворими на гострий інфаркт міокарда при використанні антагоністів альдостерону [PDF]

, 2013
Проведено аналіз віддалених результатів використання антагоністів альдостерону (спіронолактону та еплеренону) у комплексному лікуванні хворих на інфаркт міокарда з серцевою недостатністю.
Гулага, Ольга Ігорівна, Полянська, Оксана Степанівна, Тащук, Віктор Корнійович   +2 more
core  

Eplerenone

Journal of the American College of Cardiology, 2013
Bart, Bradley A., Nelson, Sarah
openaire   +1 more source